Literature DB >> 16765124

Relation of right ventricular peak systolic pressure to major adverse events in patients undergoing cardiac resynchronization therapy.

Usha B Tedrow1, Daniel B Kramer, Lynne W Stevenson, William G Stevenson, Kenneth L Baughman, Laurence M Epstein, Eldrin F Lewis.   

Abstract

The degree to which increased right-sided heart pressures influence outcome in cardiac resynchronization therapy (CRT) is unclear. High right ventricular (RV) pressures may contribute to septal malpositioning, thus hindering effective resynchronization. We hypothesized that patients with high RV systolic pressures before CRT implantation would have poorer outcome. We evaluated echocardiograms, electrocardiograms, and clinical records from 75 consecutive patients with CRT. RV systolic pressure was calculated from the peak tricuspid regurgitant, time-velocity profile. The primary end point was a composite of mortality, cardiac transplantation, or need for a left ventricular assist device. Events were evaluated by Kaplan-Meier curves and Cox proportional hazard ratios. Patients grouped by RV systolic pressure divided at the median of 35 mm Hg were similar except for more renal insufficiency and RV dysfunction when RV systolic pressure was >35 mm Hg. Univariate analysis identified RV systolic pressure >35 mm Hg (hazard ratio [HR] 3.32), diabetes (HR 2.45), renal insufficiency (HR 3.52), atrial fibrillation (HR 3.07), use of nonamiodarone antiarrhythmic medications (HR 2.86), atrial pacing (HR 2.57), and prolonged PR interval (HR 1.009) as associated with poorer outcome. Normal sinus rhythm at implantation (HR 0.34), baseline left bundle branch block (HR 0.44), and beta-blocker use (HR 0.47) were associated with improved outcome. In a multivariable model, high RV systolic pressure (HR 3.71, 95% confidence interval 1.31 to 10.4), renal insufficiency (HR 3.18, 95% confidence interval 1.29 to 7.86), and atrial fibrillation (HR 4.22, 95% confidence interval 1.54 to 11.6) remained significant. In conclusion, despite resynchronization, patients with high RV pressures have significantly decreased survival after adjusting for significant contributing influences.

Entities:  

Mesh:

Year:  2006        PMID: 16765124     DOI: 10.1016/j.amjcard.2006.01.033

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  9 in total

Review 1.  Informed consent in cardiac resynchronization therapy: what should be said?

Authors:  Daniel B Kramer; Dan W Brock; Usha B Tedrow
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2011-09

Review 2.  Current role of echocardiography in cardiac resynchronization therapy.

Authors:  Donato Mele; Matteo Bertini; Michele Malagù; Marianna Nardozza; Roberto Ferrari
Journal:  Heart Fail Rev       Date:  2017-11       Impact factor: 4.214

3.  Subharmonic microbubble emissions for noninvasively tracking right ventricular pressures.

Authors:  Jaydev K Dave; Valgerdur G Halldorsdottir; John R Eisenbrey; Joel S Raichlen; Ji-Bin Liu; Maureen E McDonald; Kris Dickie; Shumin Wang; Corina Leung; Flemming Forsberg
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-05-04       Impact factor: 4.733

Review 4.  First-degree AV block-an entirely benign finding or a potentially curable cause of cardiac disease?

Authors:  Fredrik Holmqvist; James P Daubert
Journal:  Ann Noninvasive Electrocardiol       Date:  2013-05       Impact factor: 1.468

5.  Prognostic effects of pulmonary hypertension in patients undergoing cardiac resynchronization therapy.

Authors:  Dongmei Wang; Yaling Han; Hongyun Zang; Haibo Yu; Shouli Wang; Zulu Wang; Quanmin Jing
Journal:  J Thorac Dis       Date:  2010-06       Impact factor: 2.895

6.  First-degree atrioventricular block. Clinical manifestations, indications for pacing, pacemaker management & consequences during cardiac resynchronization.

Authors:  S Serge Barold; Arzu Ilercil; Fabio Leonelli; Bengt Herweg
Journal:  J Interv Card Electrophysiol       Date:  2007-03-02       Impact factor: 1.900

7.  Relationship of soluble ST2 to pulmonary hypertension severity in patients undergoing cardiac resynchronization therapy.

Authors:  Jonathan Beaudoin; Jackie Szymonifka; Zachary Lavender; Roderick C Deaño; Qing Zhou; James L Januzzi; Jagmeet P Singh; Quynh A Truong
Journal:  J Thorac Dis       Date:  2019-12       Impact factor: 2.895

8.  Cardiac resynchronization therapy in the cardiorenal syndrome.

Authors:  Margot K Davis; Sean A Virani
Journal:  Int J Nephrol       Date:  2011-06-09

9.  Right ventricular dysfunction is a predictor of non-response and clinical outcome following cardiac resynchronization therapy.

Authors:  Francisco Alpendurada; Kaushik Guha; Rakesh Sharma; Tevfik F Ismail; Amy Clifford; Winston Banya; Raad H Mohiaddin; Dudley J Pennell; Martin R Cowie; Theresa McDonagh; Sanjay K Prasad
Journal:  J Cardiovasc Magn Reson       Date:  2011-10-31       Impact factor: 5.364

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.